ArticleFundamental & clinical pharmacology2021
Dexamethasone and p38 MAPK inhibition of cytokine production from human lung fibroblasts.
Article in Fundamental & clinical pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 14 citations in OpenAlex.
- Lignans: Advances in Biosynthesis, Bioavailability, and Pharmacological Activity.Combinatorial chemistry & high throughput screening · 2025Review
- Platelet-Rich Fibrin Increases CXCL8 Expression in Gingival Fibroblasts.Biomedicines · 2024Article
- Isolation, Identification, Anti-Inflammatory, and In Silico Analysis of New Lignans from the Resin ofPharmaceuticals (Basel, Switzerland) · 2023Article
- Effect of antiviral and immunomodulatory treatment on a cytokine profile in patients with COVID-19.Frontiers in immunology · 2023Article
- Antioxidant, Anti-Inflammatory, Anti-Menopausal, and Anti-Cancer Effects of Lignans and Their Metabolites.International journal of molecular sciences · 2022Review
- Crosstalk between p38 MAPK and GR Signaling.International journal of molecular sciences · 2022Review
- Dexamethasone and p38 MAPK inhibition of cytokine production from human lung fibroblasts.Fundamental & clinical pharmacology · 2021Article
- Role of p38 Mitogen-Activated Protein Kinase in Asthma and COPD: Pathogenic Aspects and Potential Targeted Therapies.Drug design, development and therapy · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung fibroblasts are involved in airway inflammation and remodelling in COPD. We report an investigation of the effects of combining a p38 MAPK inhibitor with a corticosteroid on cytokine production by a human lung fibroblast cell line and primary fibroblasts obtained from human lung tissue. Our main interest was to determine whether additive or synergistic anti-inflammatory effects would be observed. We observed inhibition of IL-6 and CXCL8 secretion from both lung fibroblast models by dexamethasone (maximal inhibition 40-90%) and the p38 MAPK inhibitor BIRB (maximal inhibition 30-60%), used alone and evidence of increased anti-inflammatory effects when used in combination. This combination effect was more apparent for TNF-a stimulated cytokine production (maximal inhibition increased by 10-20%). Interaction ratio analysis showed this enhanced effect to be additive rather than synergistic interaction. Similar results were obtained using both fibroblast cell culture models. Combining a p38 MAPK to corticosteroids may help reduce fibroblast mediated inflammation in COPD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.